Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity

We investigated antibody titers and avidity after heterologous versus homologous coronavirus disease 2019 vaccination over 6 months after the second dose. We found a significantly higher avidity in regimens including at least 1 dose of the adenoviral vector vaccine ChAdOx1-S compared with 2 doses of...

Descripción completa

Detalles Bibliográficos
Autores principales: Rössler, Annika, Kimpel, Janine, Fleischer, Verena, Huber, Silke, von Laer, Dorothee, Borena, Wegene, Würzner, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494481/
https://www.ncbi.nlm.nih.gov/pubmed/36111560
http://dx.doi.org/10.1093/infdis/jiac379
_version_ 1784793805498613760
author Rössler, Annika
Kimpel, Janine
Fleischer, Verena
Huber, Silke
von Laer, Dorothee
Borena, Wegene
Würzner, Reinhard
author_facet Rössler, Annika
Kimpel, Janine
Fleischer, Verena
Huber, Silke
von Laer, Dorothee
Borena, Wegene
Würzner, Reinhard
author_sort Rössler, Annika
collection PubMed
description We investigated antibody titers and avidity after heterologous versus homologous coronavirus disease 2019 vaccination over 6 months after the second dose. We found a significantly higher avidity in regimens including at least 1 dose of the adenoviral vector vaccine ChAdOx1-S compared with 2 doses of the mRNA vaccine BNT162b2.
format Online
Article
Text
id pubmed-9494481
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-94944812022-09-27 Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity Rössler, Annika Kimpel, Janine Fleischer, Verena Huber, Silke von Laer, Dorothee Borena, Wegene Würzner, Reinhard J Infect Dis Brief Report We investigated antibody titers and avidity after heterologous versus homologous coronavirus disease 2019 vaccination over 6 months after the second dose. We found a significantly higher avidity in regimens including at least 1 dose of the adenoviral vector vaccine ChAdOx1-S compared with 2 doses of the mRNA vaccine BNT162b2. Oxford University Press 2022-09-16 /pmc/articles/PMC9494481/ /pubmed/36111560 http://dx.doi.org/10.1093/infdis/jiac379 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Rössler, Annika
Kimpel, Janine
Fleischer, Verena
Huber, Silke
von Laer, Dorothee
Borena, Wegene
Würzner, Reinhard
Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity
title Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity
title_full Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity
title_fullStr Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity
title_full_unstemmed Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity
title_short Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity
title_sort regimen of coronavirus disease 2019 vaccination influences extent and kinetics of antibody avidity
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494481/
https://www.ncbi.nlm.nih.gov/pubmed/36111560
http://dx.doi.org/10.1093/infdis/jiac379
work_keys_str_mv AT rosslerannika regimenofcoronavirusdisease2019vaccinationinfluencesextentandkineticsofantibodyavidity
AT kimpeljanine regimenofcoronavirusdisease2019vaccinationinfluencesextentandkineticsofantibodyavidity
AT fleischerverena regimenofcoronavirusdisease2019vaccinationinfluencesextentandkineticsofantibodyavidity
AT hubersilke regimenofcoronavirusdisease2019vaccinationinfluencesextentandkineticsofantibodyavidity
AT vonlaerdorothee regimenofcoronavirusdisease2019vaccinationinfluencesextentandkineticsofantibodyavidity
AT borenawegene regimenofcoronavirusdisease2019vaccinationinfluencesextentandkineticsofantibodyavidity
AT wurznerreinhard regimenofcoronavirusdisease2019vaccinationinfluencesextentandkineticsofantibodyavidity
AT regimenofcoronavirusdisease2019vaccinationinfluencesextentandkineticsofantibodyavidity

Ejemplares similares